Blood Res.  2013 Jun;48(2):115-120. 10.5045/br.2013.48.2.115.

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Affiliations
  • 1Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea. cskimmd@inha.ac.kr
  • 2Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
  • 4Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 5Department of Internal Medicine, Chonbuk National University Medical School & Hospital, Jeonju, Korea.
  • 6Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • 7Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Pusan, Korea.
  • 8Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Pusan, Korea.
  • 9Department of Internal Medicine, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Korea.
  • 10Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • 11Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • 12Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.
  • 13Korean Society of Hematology Lymphoma Working Party, Korea.

Abstract

BACKGROUND
This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes.
METHODS
In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990.
RESULTS
Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration.
CONCLUSION
The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

Keyword

Diffuse large B-cell lymphoma; Epidemiology; Survival; Rituximab; CHOP regimen
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr